The UK’s first high-security robotic AI laboratory designed to accelerate the discovery of drugs and vaccines for infectious diseases has opened in Liverpool.  

The £20 million Liverpool Accelerate Laboratory has been developed through the Infection Innovation Consortium: iiCON, which advances pioneering infection R&D through collaboration between industry, researchers and the NHS. It will be available to industry and academics to develop new treatments using human organoids that provide more accurate indication of the impact of new treatments than tests based on animals. 

Due to open in 2027, the new facility will provide a safe environment where partners can work with dangerous pathogens using cutting-edge automated technology. 

The new secure Containment Level 3 (CL3) laboratory is fitted with state-of-the-art liquid handling systems, robotics, and AI. It also meets Schedule Five biohazard security requirements, meaning it is future-fit for the safe handling of dangerous pathogens. The laboratory is a high-security, steel-clad facility that responds to forthcoming changes in the Terrorism Act – making it a key UK biosecurity asset. 

As well as saving lives and supporting cutting-edge industry innovation, the laboratory is forecast to generate £40 million of investment in the first three years – creating well-paid jobs and driving research. 

Liverpool City Region Mayor, Steve Rotheram, said: “Liverpool has been leading the fight against infectious diseases for generations, and this new facility will help keep us at the cutting edge. We’re bringing together AI, robotics and world-class research into one place, which means we can develop new drugs and vaccines faster, save lives and reduce the need for animal testing.

“This is exactly the kind of investment our Life Sciences Innovation Zone was designed to deliver, creating good jobs, attracting further investment and cementing our position as a global leader in infection innovation.”

The lab’s use of organoids supports the UK Government’s £75 million national roadmap to move away from animal testing in science in favour of human-relevant, ethical and accurate alternatives. 

Open to businesses of all sizes, iiCON will support initial pilot research to enable companies to use the laboratory to explore new approaches using organoid testing – offering particular benefit to SMEs and start-ups developing novel drugs and vaccines. 

The facility will also support the next phase of iiCON’s development, bolstering the infection innovation ecosystem between industry, academia, and the NHS to enhance the discovery and route to market for new drugs and vaccines. 

A landmark launch 

Professor Janet Hemingway, Founding Director of iiCON, said: “We’re so pleased to be marking the launch of this landmark facility. Research using human organoids is at the cutting-edge of infection R&D – moving drug discovery away from animal testing and offering new ways of shaping more targeted treatments to respond to some of our most challenging infections.

“As industry responds to changing regulatory pathways, we are offering an advanced platform for pioneering experimental R&D through the development of advanced organoid models. This will support commercial innovation and accelerate the discovery and development of a new generation of drugs and vaccines. We are interested in working with companies from start-ups through to multinationals.

“A central pillar of the Liverpool City Region’s Life Sciences Innovation Zone, this facility strengthens the region’s position as a global hub for infection and reinforces iiCON and LSTM’s commitment to fostering impactful collaborations, supporting industry, and creating high-value jobs – ensuring this facility delivers real-world impact for patients, communities, and the wider economy.”